Seeking Alpha
View as an RSS Feed

DoctoRx  

View DoctoRx's Articles BY TICKER:
  • A Post-Earnings Review Of Amgen, With Discussion Of The Repatha Launch
    Today, 11:40 AM AMGN 35 Comments
  • Gilead Beats And Raises: Thinking Through The Future Of Its Business And Its Stock Price
    Wed, Jul. 29 GILD 247 Comments
  • The Importance Of Newly-Released Data For Gilead's HIV Drug Patent Cliff
    Mon, Jul. 27 GILD 77 Comments
  • Biogen Falls Hard: Is It Undervalued Now?
    Mon, Jul. 27 BIIB 55 Comments
  • An Assessment Of Celgene's Deal For Receptos
    Tue, Jul. 21 CELG 43 Comments
  • An Analysis Of Intercept Pharma, An Innovator In Serious Liver Diseases With Unmet Needs
    Editors' Pick  • Wed, Jul. 15 ICPT 60 Comments
  • A Pre-Earnings Look At Gilead Sciences
    Tue, Jul. 14 GILD 247 Comments
  • Apple: Lots Of Smoke (FUD), But What's On Fire Are Earnings And Growth Opportunities
    Fri, Jul. 10 AAPL 207 Comments
  • Biotech At A Fraught Mid-Year: An Overview And Look Ahead
    Thu, Jul. 9 ABBV, ACHN, ADXS 98 Comments
  • Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
       • Fri, Jul. 3 CELG 75 Comments
  • Vertex Pharma: Well Positioned To Set New Highs
    Fri, Jun. 26 VRTX 24 Comments
  • Is Biotech Finally In A Bubble?
    Editors' Pick  • Fri, Jun. 19 ABBV, ACHN, ALXN 246 Comments
  • Amgen, Regeneron LDL-Lowering Drugs Provide Major Upside Potential To Their Stocks
    Mon, Jun. 15 AMGN 52 Comments
  • Isis Pharmaceuticals: Another Regeneron (Or Even Better) In The Making?
    Fri, Jun. 12 ISIS 126 Comments
  • Sorrento Therapeutics And L.A.'s Richest Man Ally, Target Celgene's Blockbuster Abraxane
    Mon, Jun. 8 CELG 41 Comments
  • Portola's Lymphoma Drug Looks Good At ASCO
    Tue, Jun. 2 PTLA 25 Comments
  • Why I Bought The Dip In Amgen: Focus On Repatha And Other Aspects Of The Pipeline
    Editors' Pick  • Tue, Jun. 2 AMGN 36 Comments
  • Why I Bought The Dips In Both Gilead And Achillion Today
    Editors' Pick  • Wed, May 20 ACHN, GILD 175 Comments
  • A Critique Of Carl Icahn's Apple Fair Value Revaluation To $240 Per Share
    Tue, May 19 AAPL 109 Comments
  • Regeneron Beats, Raises And Accelerates Its Late-Stage Product Development
    Editors' Pick  • Mon, May 11 REGN 31 Comments
  • Celgene's Plan For Life After Revlimid, With Discussion Of Q1 Earnings
    Mon, May 4 CELG 33 Comments
  • Gilead Proves Golden: The Importance Of Its Beat-And-Raise Quarter
    Fri, May 1 GILD 142 Comments
  • The Case That Apple Is Worth At Least $200 A Share
    Mon, Apr. 27 AAPL 206 Comments
  • Why I Bought The Biogen Dip
    Mon, Apr. 27 BIIB 48 Comments
  • An Analysis Of Acceleron, A Development-Stage Celgene Partner
       • Wed, Apr. 22 XLRN 11 Comments
  • A Discussion Of Amgen's Q1 Results, With Updates On Its Pipeline
    Wed, Apr. 22 AMGN 14 Comments
  • Celgene: A Pre-Earnings Discussion Based On Recent News
     • Fri, Apr. 17 CELG 37 Comments
  • Why Portola's Andexanet In Phase 3 May Be Worth Much More Than Its Market Cap
       • Tue, Apr. 14 PTLA 60 Comments
  • Lumber Prices Fall Sharply: Implications For Bonds And Different Stock Market Sectors
    Tue, Apr. 14 AAPL, GILD, ITB 41 Comments
  • Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
    Thu, Apr. 9 BIIB 44 Comments
  • A Pre-Earnings Update On Gilead
       • Wed, Apr. 1 GILD 181 Comments
  • Why This Reinsurer Is Poised For Continued Outperformance
    Tue, Mar. 31 RE 29 Comments